Thus, the cardioprotection of SFI treatment in CHF for myocardial fibrosis may be achieved by upregulation of Smad7 and downregulation of TGF-β1, Smad2, and Smad3 gene expression via TGF-β/Smads signaling pathway. Here, SMAD2 is linked to congestive heart failure.